Journal of Clinical Oncology, Vol 16, 133-138, Copyright © 1998 by American Society of Clinical Oncology
Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want?
J Audrain, B Rimer, D Cella, J Garber, BN Peshkin, J Ellis, J Schildkraut, M Stefanek, V Vogel and C Lerman
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
PURPOSE: To assess preferences for the content and process of genetic
counseling and testing for breast-ovarian cancer susceptibility among women
at high risk for breast cancer. METHODS: Ninety-eight healthy women who had
a family history of breast cancer in at least two first- degree relatives
participated in a structured telephone survey that evaluated preferences
for type of provider and the content and process of pretest education and
posttest genetic counseling. RESULTS: Forty- two percent of women preferred
that pretest education be delivered by a genetic counselor, while 22%
preferred an oncologist. This preference was positively associated with a
desire to discuss psychosocial issues during the session (P = .001). For
posttest counseling, 38% of women preferred an oncologist, while 20%
preferred a genetic counselor. However, women who desired supportive
counseling during this session were significantly more likely to prefer a
genetic counselor to an oncologist (P = .02). Fewer women wished to see a
primary care physician or gynecologist for pretest education (11%) or
posttest counseling (22%). With regard to the counseling process, 82% of
women wished to self-refer for genetic counseling, but 63% desired advice
and recommendations about whether to be tested. CONCLUSION: When feasible,
the optimal approach may be for oncologists to work with genetic counselors
to provide pretest education and medical recommendations. Elicitation of
patients' preferences may be useful to determine the level of counseling
services needed.
This article has been cited by other articles:
|
|
|
|
 
D. Blain and B. P. Brooks
Molecular Diagnosis and Genetic Counseling in Ophthalmology
Arch Ophthalmol,
February 1, 2007;
125(2):
196 - 203.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Osaka, M. Yashiro, T. Sawada, K. Katsuragi, and K. Hirakawa
Is a Lymph Node Detected by the Dye-Guided Method a True Sentinel Node in Gastric Cancer?
Clin. Cancer Res.,
October 15, 2004;
10(20):
6912 - 6918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Halbert, L. Wenzel, C. Lerman, B. N. Peshkin, S. Narod, A. Marcus, C. Corio, T. Demarco, and S. Bellamy
Predictors of Participation in Psychosocial Telephone Counseling following Genetic Testing for BRCA1 and BRCA2 Mutations
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2004;
13(5):
875 - 881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cullen, M. D. Schwartz, W. F. Lawrence, J. V. Selby, and J. S. Mandelblatt
Short-Term Impact of Cancer Prevention and Screening Activities on Quality of Life
J. Clin. Oncol.,
March 1, 2004;
22(5):
943 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Peshkin, C. Isaacs, C. Finch, S. Kent, and M. D. Schwartz
Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians
J. Clin. Oncol.,
December 1, 2003;
21(23):
4322 - 4328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wideroff, A. N. Freedman, L. Olson, C. N. Klabunde, W. Davis, K. P. Srinath, R. T. Croyle, and R. Ballard-Barbash
Physician Use of Genetic Testing for Cancer Susceptibility: Results of a National Survey
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2003;
12(4):
295 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Chen, J. E. Garber, S. Higham, K. A. Schneider, K. B. Davis, A. M. Deffenbaugh, T. S. Frank, R. S. Gelman, and F. P. Li
BRCA1/2 Genetic Testing in the Community Setting
J. Clin. Oncol.,
November 15, 2002;
20(22):
4485 - 4492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J van Asperen, S van Dijk, M W Zoeteweij, D R M Timmermans, G H de Bock, E J Meijers-Heijboer, M F Niermeijer, M H Breuning, J Kievit, and W Otten
What do women really want to know? Motives for attending familial breast cancer clinics
J. Med. Genet.,
June 1, 2002;
39(6):
410 - 414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Welkenhuysen, G Evers-Kiebooms, M Decruyenaere, E Claes, and L Denayer
A community based study on intentions regarding predictive testing for hereditary breast cancer
J. Med. Genet.,
August 1, 2001;
38(8):
540 - 547.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Lawrence, B. N. Peshkin, W. Liang, C. Isaacs, C. Lerman, and J. S. Mandelblatt
Cost of Genetic Counseling and Testing for BRCA1 and BRCA2 Breast Cancer Susceptibility Mutations
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2001;
10(5):
475 - 481.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. N. Peshkin, T. A. DeMarco, B. M. Brogan, C. Lerman, and C. Isaacs
BRCA1/2 Testing: Complex Themes in Result Interpretation
J. Clin. Oncol.,
May 1, 2001;
19(9):
2555 - 2565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A Metcalfe, A. Liede, E. Hoodfar, A. Scott, W. D Foulkes, and S. A Narod
An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling
J. Med. Genet.,
November 1, 2000;
37(11):
866 - 874.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. MEISER, P. BUTOW, A. BARRATT, G. SUTHERS, M. SMITH, A. COLLEY, E. THOMPSON, and K. TUCKER
Attitudes to genetic testing for breast cancer susceptibility in women at increased risk of developing hereditary breast cancer
J. Med. Genet.,
June 1, 2000;
37(6):
472 - 476.
[Full Text]
|
|
|
|
|
|
|
L. G. Bluman, B. K. Rimer, D. A. Berry, N. Borstelmann, J. D. Iglehart, K. Regan, J. Schildkraut, and E. P. Winer
Attitudes, Knowledge, and Risk Perceptions of Women With Breast and/or Ovarian Cancer Considering Testing for BRCA1 and BRCA2
J. Clin. Oncol.,
March 1, 1999;
17(3):
1040 - 1040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Frank
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist
Oncologist,
December 1, 1998;
3(6):
403 - 412.
[Abstract]
[Full Text]
|
|
|
|
